See how well ICG fluorescence can show knee tissue blood flow during arthroscopy
Official title: Intraoperative Evaluation of Blood Flow for Knee Arthroscopy Using Indocyanine Green Fluorescence Angiography
Run by Henry Ford Health System · NCT07793266 · Data updated 2026-11-12
This study tests whether injecting a dye called ICG can help doctors see blood flow in knee tissues during arthroscopic knee surgery, including different ACL tear severities.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 14 Years to 89 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | March 1, 2027 |
| Study ends | March 1, 2027 |
| Registry record updated | August 28, 2026 |
| Trial ID | NCT07793266 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Candidates are patients aged 14–89 undergoing knee arthroscopy at Henry Ford Center for Athletic Medicine who can consent and comply with the protocol.
✕Probably not a fit
Patients with iodide allergy, recent iodinated studies, prior targeted surgery, pregnancy, or other safety exclusions may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase interventional study evaluates the feasibility and visualization capability of indocyanine green (ICG) fluorescence imaging to assess tissue perfusion in the knee during arthroscopy. It compares fluorescence visualization across ACL tear grades and aims to identify an optimal ICG dose and timing for intraoperative use. Participants are adults and adolescents undergoing knee arthroscopy who meet consent and safety criteria. Four dose levels of SPY Agent Green (5, 7.5, 10, and 12.5 mg) are tested to determine intraoperative visualization kinetics. Safety and feasibility outcomes are collected to inform future larger studies.
Why it matters
Potential benefit: If successful, this approach could improve real-time assessment of knee tissue blood flow during surgery, potentially guiding interventions.
How similar studies have gone: Previous uses of ICG fluorescence in orthopedic surgery have shown feasibility for imaging perfusion, supporting this exploratory approach in the knee.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients undergoing knee arthroscopy with a HFH Orthopaedic surgeon * Patients must be within ages of 14-89. Patient ages 14-17 will be included to capture an important sporting demographic who sustain ACL injuries which would stand to benefit from this intervention if successful. * Have signed an approved informed consent form for the study. * Be willing to comply with the protocol Exclusion Criteria: * Patient is less than 14 years of age or greater than 89 years of age * Patients who have had iodide-based radiology studies within the last seven (7) days prior to surgery * Previous surgical repair of targeted surgical area * Known allergy or history of adverse reaction to SPY Agent Green, ICG, * Subjects who have participated in another investigational study within 30 days prior to surgery. * Pregnant or lactating subjects. * Subjects who, in the Investigator's opinion, have any medical condition that may make the subject a poor candidate for the investigational procedure, or interfere with the interpretation of study results.
Where it's running
-
Henry Ford Center for Athletic Medicine
Detroit, Michigan, United States Recruiting
Study contacts
- Principal investigator: Vasilios Moutzouros, MD — Henry Ford Health System
- Study coordinator: Maxim A Jani, BS
- Email: mjani1@hfhs.org
- Phone: 2488240579
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can Gleolan help highlight kidney tumors during partial nephrectomy?
This study tests whether giving Gleolan before kidney surgery helps fluorescence identify cancer tissue in adults with suspected kidney cancer undergoing partial nephrectomy.
-
Long-acting local pain medicine after knee replacement
This study tests whether a new extended-release pain medicine (Zynrelef) given around the knee during total knee replacement can reduce pain after surgery better or as well as standard injections or nerve blocks.
-
Can blood and physical tests before transplant predict non-relapse mortality
This study tests whether pre-transplant blood markers and physical tests can predict non-relapse mortality in adults undergoing stem cell therapy.
-
Multimodal Pain Plan to Cut Opioids After Hip Replacement
This study tests whether a multimodal pain regimen with a printed opioid prescription (instead of pharmacy-direct dispensing) can control pain after hip replacement while reducing opioid use.
-
Peanut intake and liver health in adults with MASLD
This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.
-
Comparing targeted Y-90 radioembolization with focused external SBRT for liver cancer
This trial tests whether Y-90 transarterial radioembolization or focused stereotactic body radiation (SBRT) better controls hepatocellular carcinoma lesions in adults eligible for either treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.